- Exact Sciences secures significant Medicare coverage for its oncodetect test, poised to enhance colorectal cancer treatment.
- Analysts' average price target suggests a potential 24.53% upside for EXAS.
- GuruFocus estimates a fair value of $78.00 for EXAS, indicating a potential 40.77% increase.
Exact Sciences Corp (EXAS, Financial) has achieved a pivotal milestone by securing Medicare coverage for its innovative oncodetect test. This vital development is set to significantly enhance the detection and ongoing monitoring of residual disease in patients battling colorectal cancer. Under the new coverage, the oncodetect test is approved for use in individuals diagnosed with stage II, III, and resectable stage IV cancers, facilitating essential surveillance over a five-year timeline.
Wall Street's Perspective: Analyst Price Targets
According to the projections provided by 24 respected analysts, the average one-year price target for Exact Sciences Corp is currently set at $69.00. This assessment includes a high estimate of $90.00 and a low estimate of $54.00. At the current trading price of $55.41, the average target price suggests a potential upside of 24.53%. For further details and in-depth analysis, please visit the Exact Sciences Corp (EXAS, Financial) Forecast page.
Market Sentiment: Broker Recommendations
The consensus recommendation from 27 brokerage firms positions Exact Sciences Corp with an average brokerage recommendation of 1.7. This rating corresponds to an "Outperform" status on a scale where 1 denotes a Strong Buy and 5 indicates a Sell.
GuruFocus Insights: GF Value Estimations
According to GuruFocus's proprietary metrics, the anticipated GF Value for Exact Sciences Corp over a year is $78.00. This valuation forecasts a substantial upside of 40.77% from the current price of $55.41. The GF Value reflects GuruFocus's estimation of the stock's fair trading value, derived from historical pricing multiples, past growth patterns, and forecasts of future performance. For more comprehensive data, explore the Exact Sciences Corp (EXAS, Financial) Summary page.
